Fig. 5

Functional profiling performed with PICRUSt2 based on the KEGG pathway map [43]. A T2 vs. T3 in women with TPOAb-positive SCH and no LT₄ treatment. B T2 vs. T3 in women with TPOAb-negative SCH and no LT₄ treatment. C T2 vs. T3 in women with TPOAb-positive SCH and LT₄ treatment. D T2 vs. T3 in women with TPOAb-negative SCH and LT₄ treatment. LDA value distribution histogram: the green and red bars indicate the metabolic functions with higher abundance in T2 and T3, respectively. AZ1, TPOAb⁺-LT₄⁻-T2; AW1, TPOAb⁺-LT₄⁻-T3; BZ1, TPOAb⁻-LT₄⁻-T2; BW1, TPOAb⁻-LT₄⁻-T3; AZ2, TPOAb⁺-LT₄⁺-T2; AW2, TPOAb⁺-LT₄⁺-T3; BZ2, TPOAb⁻-LT₄⁺-T2; BW2, TPOAb⁻-LT₄⁺-T3